On March 19th, 2014, MacOrtho held its first Centre for Evidence-Based Orthopaedics (CEO) educational event, Research Program Management Sessions (RPMs): Driving Success. Dr. Michelle Ghert presented a talk entitled “International Randomized Trials in Orthopaedic Oncology: An International Collaborative Network” which focused on the need for higher level evidence in the field of orthopaedic oncology and the elements required to successfully implement randomized controlled trials (RCT). The talk showcased the
Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) trial which is the first RCT in the field of orthopaedic oncology.
The PARITY trial is currently demonstrating strong feasibility in its vanguard phase, with 38 patients enrolled to date across 11 sites in, Canada the US and Australia. Over 40 surgeons from 11 countries around the world have expressed interest in participating in the definitive phase of this ground-breaking cancer surgery trial. The rationale for this study is fuelled by:
1) Increased infection rate outcomes in bone tumor surgery compared to general Arthroplasty.
2) A lack of consensus among orthopaedic oncologists regarding the most effective prophylactic antibiotic regimen.
3) A lack of randomized controlled trial (RCT) evidence.
4) Extensive investigator support for the proposed trial.
These management sessions are one of the many ways MacOrtho shows its commitment to the principles and practices of evidence based orthopaedics.